C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Pharming Technologies B.V.
Information provided by (Responsible Party):
Pharming Technologies B.V.
ClinicalTrials.gov Identifier:
First received: July 18, 2011
Last updated: January 7, 2015
Last verified: July 2014

This is a non-interventional treatment Registry of Hereditary Angioedema (HAE) patients treated with C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest), to observe adverse events and insufficient efficacy, and to assess the immunological profile following single and repeated treatment with Ruconest.

Condition Intervention
Hereditary Angioedema
Drug: rhC1INH or pdC1INH

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: C1 Inhibitor Treatment Registry to Assess the Safety and Immunological Profile of Ruconest in the Treatment of HAE Attacks

Resource links provided by NLM:

Further study details as provided by Pharming Technologies B.V.:

Primary Outcome Measures:
  • The primary objective is to observe the adverse event profile and insufficient efficacy, following single and repeated treatment with Ruconest or pdC1INHof acute angioedema attacks [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • To assess the immunological profile of Ruconest (for suspected hypersensitivity or suspected neutralizing antibodies) [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 300
Study Start Date: July 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Hereditary Angioedema Drug: rhC1INH or pdC1INH
C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
Other Name: Ruconest

Detailed Description:

see below


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The aim is to recruit 300 patients treated with Ruconest. Additionally, the study will continue until 100 patients have been exposed to Ruconest for at least 3 attacks. Enrolment in the pdC1INH arm will be unrestricted.


Inclusion Criteria:

  • Decision to treat the HAE patient with C1 inhibitor (either Ruconest or pdC1INH)
  • Patients must give written informed consent

Exclusion Criteria:

  • A diagnosis of acquired C1INH deficiency (AAE)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01397864

Contact: Tessa Heikamp +31 71 5247 400 t.heikamp@pharming.com

For information on sites in Europe, please contact Pharming Technologies Recruiting
Leiden, Netherlands, 2333 CR
Contact: See central contact         
Sponsors and Collaborators
Pharming Technologies B.V.
Study Director: Anurag Relan, MD Pharming Technologies BV
  More Information

No publications provided

Responsible Party: Pharming Technologies B.V.
ClinicalTrials.gov Identifier: NCT01397864     History of Changes
Other Study ID Numbers: C1 1412
Study First Received: July 18, 2011
Last Updated: January 7, 2015
Health Authority: European Union: European Medicines Agency

Keywords provided by Pharming Technologies B.V.:
Hereditary Angioedema
Recombinant C1 Inhibitor

Additional relevant MeSH terms:
Angioedemas, Hereditary
Cardiovascular Diseases
Genetic Diseases, Inborn
Hypersensitivity, Immediate
Immune System Diseases
Skin Diseases
Skin Diseases, Vascular
Vascular Diseases

ClinicalTrials.gov processed this record on March 25, 2015